PFE
Pfizer Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.
Market Cap: 154 Billion
Primary Exchange: NEW YORK STOCK EXCHANGE INC.
Website: https://www.pfizer.com/
Shares Outstanding: 5.65 Billion
Float: 0
Dividend: 1.616626537236101 (0.06%)
Beta: 0.40794723497039814
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 826 trading days
From: 2018-11-30 To: 2024-03-07
Lowest Point:
Mid-stage study underway for Progenics' I-131 1095 in prostate cancer
via: SeekingAlpha at 2019-06-13 04:50:33:000
The first patient has been dosed in a Phase 2 clinical trial, ARROW , evaluating Progenics Pharmaceuticals' (NASDAQ: PGNX ) I-131 1095 radiotherapy, combined with Pfizer (NYSE: PFE ) and Astellas' ( OTCPK:ALPMY ) XTANDI (enzalutamide), for the treatment of metastatic castration-res… read more...
Key events next week - healthcare
via: SeekingAlpha at 2019-06-13 03:28:10:000
Noteworthy events during the week of June 16 - 22 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Merck & Co., Inc., IQVIA Holdings Inc., Healthcare stocks news, , Read more … read more...
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
Study supports use of Pfizer's Xeljanz alone in rheumatoid arthritis
via: SeekingAlpha at 2019-06-12 05:02:26:000
Results from a Phase 3b/4 clinical trial, ORAL Shift, evaluating the efficacy of Pfizer's (NYSE: PFE ) XELJANZ (tofacitinib) XR after the withdrawal of methotrexate in adults with moderately to severely active rheumatoid arthritis (RA) showed it to be non-inferior (no worse than) to XELJA… read more...
Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor
via: Business Wire at 2019-06-12 04:00:00:000
Results to be Presented During a Late-Breaking Oral Session at the Annual European Congress of Rheumatology (EULAR 2019) Pfizer Inc. (NYSE:PFE) announced today positive results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthri… read more...
A Missed Alzheimer's Opportunity? Not So Much
via: SeekingAlpha at 2019-06-12 02:20:30:000
The Washington Post made quite a splash with this story about Pfizer (PFE), Enbrel ( etanercept ), and Alzheimer's disease. There's already been a lot of comment about it on June 5 on Twitter and in some other venues , but I thought it might be useful to try to sum things up in an easily … read more...
Novartis Kisqali Might Have A Path Forward To Take On Pfizer's Ibrance
via: SeekingAlpha at 2019-06-11 16:14:01:000
Novartis ( NVS ) announced positive results from its phase 3 study using its cancer drug Kisqali to treat patients with HER+/HER2- advanced breast cancer. The study showed that treatment with Kisqali extends survival for these patients. These results were presented as a late-breaker at the… read more...
Dividend Arbitrage For Pfizer
via: SeekingAlpha at 2019-06-10 12:49:16:000
I have neglected Pfizer ( PFE ) since I recommended it back when it was trading at $27. Since then, it has risen 60%. I was recently asked whether this stock is a good buy for the summer season, where the Sell in May and Go Away phenomenon tends to bring down even blue-chip s… read more...
Dividend Arbitrage For Pfizer
via: SeekingAlpha at 2019-06-10 12:49:16:000
I have neglected Pfizer ( PFE ) since I recommended it back when it was trading at $27. Since then, it has risen 60%. I was recently asked whether this stock is a good buy for the summer season, where the Sell in May and Go Away phenomenon tends to bring down even blue-chip s… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|---|---|---|---|---|---|---|---|
| 2019-11-07 | 2019-12-02 | 2019-11-08 | 2019-09-24 | 0.36 | No Change QoQ | |||
| 2019-08-01 | 2019-09-03 | 2019-08-02 | 2019-06-27 | 0.36 | No Change QoQ | |||
| 2019-05-09 | 2019-06-07 | 2019-05-10 | 2019-04-25 | 0.36 | No Change QoQ | |||
| 2019-01-31 | 2019-03-01 | 2019-02-01 | 2018-12-14 | 0.36 | Increase | |||
| 2018-11-08 | 2018-12-03 | 2018-11-09 | 2018-09-27 | 0.34 | No Change QoQ | |||
| 2018-08-02 | 2018-09-04 | 2018-08-03 | 2018-06-28 | 0.34 | No Change QoQ | |||
| 2018-05-10 | 2018-06-01 | 2018-05-11 | 2018-04-26 | 0.34 | No Change QoQ | |||
| 2018-02-01 | 2018-03-01 | 2018-02-02 | 2017-12-18 | 0.34 | Increase | |||
| 2017-11-09 | 2017-12-01 | 2017-11-10 | 2017-09-27 | 0.32 | No Change QoQ | |||
| 2017-08-02 | 2017-09-01 | 2017-08-04 | 2017-06-22 | 0.32 | No Change QoQ | |||
| 2017-05-10 | 2017-06-01 | 2017-05-12 | 2017-04-27 | 0.32 | No Change QoQ | |||
| 2017-02-01 | 2017-03-01 | 2017-02-03 | 2016-12-12 | 0.32 | Increase | |||
| 2016-11-09 | 2016-12-01 | 2016-11-11 | 2016-09-22 | 0.3 | No Change QoQ | |||
| 2016-08-03 | 2016-09-01 | 2016-08-05 | 2016-06-23 | 0.3 | No Change QoQ | |||
| 2016-05-11 | 2016-06-01 | 2016-05-13 | 2016-04-28 | 0.3 | No Change QoQ | |||
| 2016-02-03 | 2016-03-02 | 2016-02-05 | 2015-12-14 | 0.3 | Increase | |||
| 2015-11-04 | 2015-12-01 | 2015-11-06 | 2015-09-25 | 0.28 | No Change QoQ | |||
| 2015-08-05 | 2015-09-02 | 2015-08-07 | 2015-06-25 | 0.28 | No Change QoQ | |||
| 2015-05-06 | 2015-06-02 | 2015-05-08 | 2015-04-23 | 0.28 | No Change QoQ | |||
| 2015-02-04 | 2015-03-03 | 2015-02-06 | 2014-12-15 | 0.28 | Increase | |||
| 2014-11-05 | 2014-12-02 | 2014-11-07 | 2014-10-23 | 0.26 | No Change QoQ | |||
| 2019-11-07 | 2019-12-02 | 2019-11-08 | 2019-09-24 | 0.36 | Cash | |||
| 2020-01-30 | 2020-03-06 | 2020-01-31 | 2019-12-16 | 0.38 | Cash | |||
| 2020-05-07 | 2020-06-05 | 2020-05-08 | 2020-04-23 | 0.38 | Cash | |||
| 2020-07-30 | 2020-09-01 | 2020-07-31 | 2020-06-25 | 0.38 | Cash | |||
| 2020-11-05 | 2020-12-01 | 2020-11-06 | 2020-09-24 | 0.38 | Cash | |||
| 2023-01-26 | 2023-03-03 | 2023-01-27 | 2022-12-09 | 0.41 | Cash | |||
| 2023-05-11 | 2023-06-09 | 2023-05-12 | 2023-04-26 | 0.41 | Cash | |||
| 2023-07-27 | 2023-09-05 | 2023-07-28 | 2023-06-22 | 0.41 | Cash | |||
| 2023-11-09 | 2023-12-04 | 2023-11-10 | 2023-10-04 | 0.41 | Cash | |||
| 2024-01-25 | 2024-03-01 | 2024-01-26 | 2023-12-14 | 0.42 | Cash |
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|